loratadine has been researched along with Sneezing in 16 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Sneezing: The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 9.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 5.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| " and intracerebroventricular pentobarbital-induced sedation and alcohol-induced ataxia models." | 3.76 | Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. ( Bagad, AS; Bahekar, PC; Chidrewar, GU; Mandhane, SN; Mehetre, SV; Pawar, CA; Rajamannar, T; Rao, CT; Shah, JH, 2010) |
| "Sneezing and nasal scratching after challenges were significantly ameliorated in the Shu-Bi-Lin-treated group compared with the ovalbumin-sensitized and untreated group, but rhinorrhea volume was not reduced." | 3.73 | Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis. ( Chen, GG; Leung, PC; van Hasselt, CA; Wang, LH; Wong, YO; Woo, JK; Zhao, Y, 2006) |
| "Montelukast is a leukotriene receptor antagonist recently approved for the treatment of seasonal allergic rhinitis (SAR)." | 2.71 | Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. ( Arastu, R; Baidoo, CA; Faris, MA; Howland, WC; Klein, KC; Philpot, EE; Ratner, PH; Rickard, KA, 2003) |
| "Azelastine nasal spray is an effective treatment for patients with seasonal allergic rhinitis who do not respond to loratadine and is an alternative to switching to another oral antihistamine or to using multiple antihistamines." | 2.71 | Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. ( Berger, WE; White, MV, 2003) |
| "Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period." | 2.71 | The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005) |
| "Treatment with loratadine resulted in a significant inhibition of the histamine-induced changes in both nasal and sinus cavities." | 2.69 | Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine. ( Baroody, FM; Blair, C; deTineo, M; Gungor, A; Haney, L; Naclerio, RM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Yan, X | 1 |
| Gai, J | 1 |
| Han, J | 1 |
| Zhang, H | 1 |
| Luo, H | 1 |
| Huang, S | 1 |
| Wang, J | 1 |
| Grubbe, RE | 1 |
| Lumry, WR | 1 |
| Anolik, R | 1 |
| Mandhane, SN | 1 |
| Shah, JH | 1 |
| Bahekar, PC | 1 |
| Mehetre, SV | 1 |
| Pawar, CA | 1 |
| Bagad, AS | 1 |
| Chidrewar, GU | 1 |
| Rao, CT | 1 |
| Rajamannar, T | 1 |
| Demoly, P | 1 |
| Dreyfus, I | 1 |
| Dhivert-Donnadieu, H | 1 |
| Mesbah, K | 1 |
| Bachert, C | 1 |
| Maurer, M | 1 |
| Ratner, PH | 1 |
| Howland, WC | 1 |
| Arastu, R | 1 |
| Philpot, EE | 1 |
| Klein, KC | 1 |
| Baidoo, CA | 1 |
| Faris, MA | 1 |
| Rickard, KA | 1 |
| Berger, WE | 1 |
| White, MV | 1 |
| Hyo, S | 1 |
| Fujieda, S | 1 |
| Kawada, R | 1 |
| Kitazawa, S | 1 |
| Takenaka, H | 1 |
| Montaño Velázquez, BB | 1 |
| Jáuregui-Renaud, K | 1 |
| Bañuelos Arias, Adel C | 1 |
| Ayala, JC | 1 |
| Martínez, MD | 1 |
| Campillo Navarrete, R | 1 |
| Rosalia, IS | 1 |
| Salazar, Mdel R | 1 |
| Serrano, HA | 1 |
| Mondragón, AO | 1 |
| Perez, RL | 1 |
| Zhao, Y | 1 |
| van Hasselt, CA | 1 |
| Woo, JK | 1 |
| Chen, GG | 1 |
| Wong, YO | 1 |
| Wang, LH | 1 |
| Leung, PC | 1 |
| Buczyłko, K | 1 |
| Chwała, C | 1 |
| Zielińska-Bliźniewska, H | 1 |
| Wagner, A | 1 |
| Dzwonnik, A | 1 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Baroody, FM | 1 |
| Gungor, A | 1 |
| deTineo, M | 1 |
| Haney, L | 1 |
| Blair, C | 1 |
| Naclerio, RM | 1 |
| Muether, PS | 1 |
| Gwaltney, JM | 1 |
| Horak, F | 1 |
| Stübner, UP | 1 |
| Zieglmayer, R | 1 |
| Harris, AG | 1 |
| Frølund, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen[NCT00867191] | Phase 4 | 233 participants (Actual) | Interventional | 2002-02-01 | Completed | ||
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
1 review available for loratadine and Sneezing
| Article | Year |
|---|---|
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
12 trials available for loratadine and Sneezing
| Article | Year |
|---|---|
Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.
Topics: Adult; Anti-Allergic Agents; Drugs, Chinese Herbal; Female; Fluticasone; Humans; Loratadine; Male; M | 2019 |
Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Method; Drug Synergism; Drug The | 2009 |
Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
Topics: Adult; Antigens, Plant; Cupressus; Disease Progression; Double-Blind Method; Female; France; Histami | 2009 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Method; Dru | 2003 |
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine | 2005 |
Vitamin E effects on nasal symptoms and serum specific IgE levels in patients with perennial allergic rhinitis.
Topics: Adolescent; Adult; Allergens; Antioxidants; Child; Dietary Supplements; Double-Blind Method; Ephedri | 2006 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Antagonists; Humans; | 1999 |
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.
Topics: Adult; Common Cold; Histamine H1 Antagonists; Humans; Intercellular Adhesion Molecule-1; Loratadine; | 2001 |
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine | 2002 |
Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Beclomethasone; Cyproheptadine; Doubl | 1991 |
3 other studies available for loratadine and Sneezing
| Article | Year |
|---|---|
Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H.
Topics: Acetates; Alcohols; Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ataxia; Cetirizin | 2010 |
Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis.
Topics: Animals; Anti-Allergic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Eosinophils; Guinea Pi | 2006 |
[The influence of desloratadine on course of intermittens allergic rhinitis].
Topics: Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Disease Progression; Female; H | 2005 |